Development of erythropoietin receptor-targeted drug delivery system against breast cancer using tamoxifen-loaded nanostructured lipid carriers

Tamoxifen (TAM) has been used in the treatment of breast cancers and is supplemented with erythropoietin (EPO) to alleviate the cancer-related anemia. The purported deleterious effects caused by the use of EPO with chemotherapeutic agents in the treatment of cancer-related anemia vary across studies...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Drug Des Devel Ther
Κύριοι συγγραφείς: Beh, Chaw Yee, How, Chee Wun, Foo, Jhi Biau, Foong, Jia Ning, Selvarajah, Gayathri Thevi, Rasedee, Abdullah
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Dove Medical Press 2017
Θέματα:
Original Research
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5358988/
https://ncbi.nlm.nih.gov/pubmed/28352153
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S123939
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια